高壁垒赛道杀出重磅BD,中生估值迎来重塑时刻

中国医药创新促...
Mar 05

本文转载自深蓝观作者:旧梦中国创新药的出海授权(BD)已日趋常态化,但2026开年,一笔总金额15.3亿美元的重磅BD,却吸引全行业关注。3月4日,中国生物制药(01177.HK)早盘公告,就全球首创JAK/ROCK双靶点抑制剂罗伐昔替尼与赛诺菲达成独家全球许可协议,中生有权获最高15.3亿美元的付款,其中包括1.35亿美元的首付款以及潜在开发、监管及销售里程碑付款,另外还将获得基于年度净销售额的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10